FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028541316> ?p ?o ?g. }

• W2028541316 endingPage "632" @default.
• W2028541316 startingPage "624" @default.
• W2028541316 abstract "BackgroundAlthough a left ventricular assist device is often used to provide circulatory support until transplantation in severe heart failure, the mortality of long-term use of left ventricular assist devices remains high. We have shown that hepatocyte growth factor causes angiogenesis, antifibrosis, and antiapoptosis in the myocardium. Therefore, gene therapy with hepatocyte growth factor–complementary DNA plasmids may enhance the chance of “bridge to recovery.” In this study, we performed gene therapy with hepatocyte growth factor in the impaired goat heart with a left ventricular assist device.MethodsCardiac impairment was induced in 6 adult goats (56-65 kg) by ligation of the coronary artery, and ventricular assist devices were installed. The hepatocyte growth factor group (HGF; n = 3) was administered human hepatocyte growth factor–complementary DNA plasmid (2.0 mg) in the myocardium. The control group (n = 3) was similarly administered β-galactosidase plasmid. Four weeks after gene transfection, we attempted to wean all goats from the ventricular assist device.ResultsThe myocardia transfected with human hepatocyte growth factor–complementary DNA contained human hepatocyte growth factor protein at levels as high as 1.0 ± 0.3 ng/g tissue 3 days after transfection. After weaning from the ventricular assist device, the HGF group showed good hemodynamics, whereas the control group showed deterioration. The percentage of fractional shortening was significantly higher in the HGF group than the control group (HGF vs control, 37.9% ± 1.7% vs 26.4% ± 0.3%, respectively; P < .01). Left ventricular dilatation associated with myocyte hypertrophy and fibrotic changes was detected in the control group but not in the HGF group. Vascular density was markedly increased in the HGF group.ConclusionsThese results suggest that gene therapy with human hepatocyte growth factor may enhance the chance of bridge to recovery in the impaired heart supported with a ventricular assist device. Although a left ventricular assist device is often used to provide circulatory support until transplantation in severe heart failure, the mortality of long-term use of left ventricular assist devices remains high. We have shown that hepatocyte growth factor causes angiogenesis, antifibrosis, and antiapoptosis in the myocardium. Therefore, gene therapy with hepatocyte growth factor–complementary DNA plasmids may enhance the chance of “bridge to recovery.” In this study, we performed gene therapy with hepatocyte growth factor in the impaired goat heart with a left ventricular assist device. Cardiac impairment was induced in 6 adult goats (56-65 kg) by ligation of the coronary artery, and ventricular assist devices were installed. The hepatocyte growth factor group (HGF; n = 3) was administered human hepatocyte growth factor–complementary DNA plasmid (2.0 mg) in the myocardium. The control group (n = 3) was similarly administered β-galactosidase plasmid. Four weeks after gene transfection, we attempted to wean all goats from the ventricular assist device. The myocardia transfected with human hepatocyte growth factor–complementary DNA contained human hepatocyte growth factor protein at levels as high as 1.0 ± 0.3 ng/g tissue 3 days after transfection. After weaning from the ventricular assist device, the HGF group showed good hemodynamics, whereas the control group showed deterioration. The percentage of fractional shortening was significantly higher in the HGF group than the control group (HGF vs control, 37.9% ± 1.7% vs 26.4% ± 0.3%, respectively; P < .01). Left ventricular dilatation associated with myocyte hypertrophy and fibrotic changes was detected in the control group but not in the HGF group. Vascular density was markedly increased in the HGF group. These results suggest that gene therapy with human hepatocyte growth factor may enhance the chance of bridge to recovery in the impaired heart supported with a ventricular assist device." @default.
• W2028541316 created "2016-06-24" @default.
• W2028541316 creator A5045683397 @default.
• W2028541316 creator A5058261979 @default.
• W2028541316 creator A5064951102 @default.
• W2028541316 creator A5073902661 @default.
• W2028541316 creator A5084319283 @default.
• W2028541316 creator A5084356588 @default.
• W2028541316 creator A5091657288 @default.
• W2028541316 date "2005-09-01" @default.
• W2028541316 modified "2023-09-29" @default.
• W2028541316 title "Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices" @default.
• W2028541316 cites W121724811 @default.
• W2028541316 cites W1569560733 @default.
• W2028541316 cites W1967744276 @default.
• W2028541316 cites W1969055985 @default.
• W2028541316 cites W1990224341 @default.
• W2028541316 cites W1997780004 @default.
• W2028541316 cites W2003733359 @default.
• W2028541316 cites W2010768185 @default.
• W2028541316 cites W2025311714 @default.
• W2028541316 cites W2035694533 @default.
• W2028541316 cites W2044666189 @default.
• W2028541316 cites W2053009552 @default.
• W2028541316 cites W2056804173 @default.
• W2028541316 cites W2061149882 @default.
• W2028541316 cites W2061719893 @default.
• W2028541316 cites W2067249488 @default.
• W2028541316 cites W2067943009 @default.
• W2028541316 cites W2071110875 @default.
• W2028541316 cites W2072740783 @default.
• W2028541316 cites W2091349813 @default.
• W2028541316 cites W2093149476 @default.
• W2028541316 cites W2097149135 @default.
• W2028541316 cites W2104898886 @default.
• W2028541316 cites W2120337309 @default.
• W2028541316 cites W2138080145 @default.
• W2028541316 cites W2147135453 @default.
• W2028541316 cites W2164409993 @default.
• W2028541316 cites W2534065002 @default.
• W2028541316 doi "https://doi.org/10.1016/j.jtcvs.2004.02.045" @default.
• W2028541316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16153905" @default.
• W2028541316 hasPublicationYear "2005" @default.
• W2028541316 type Work @default.
• W2028541316 sameAs 2028541316 @default.
• W2028541316 citedByCount "22" @default.
• W2028541316 countsByYear W20285413162012 @default.
• W2028541316 countsByYear W20285413162013 @default.
• W2028541316 countsByYear W20285413162014 @default.
• W2028541316 countsByYear W20285413162015 @default.
• W2028541316 countsByYear W20285413162016 @default.
• W2028541316 countsByYear W20285413162018 @default.
• W2028541316 countsByYear W20285413162021 @default.
• W2028541316 countsByYear W20285413162022 @default.
• W2028541316 crossrefType "journal-article" @default.
• W2028541316 hasAuthorship W2028541316A5045683397 @default.
• W2028541316 hasAuthorship W2028541316A5058261979 @default.
• W2028541316 hasAuthorship W2028541316A5064951102 @default.
• W2028541316 hasAuthorship W2028541316A5073902661 @default.
• W2028541316 hasAuthorship W2028541316A5084319283 @default.
• W2028541316 hasAuthorship W2028541316A5084356588 @default.
• W2028541316 hasAuthorship W2028541316A5091657288 @default.
• W2028541316 hasBestOaLocation W20285413161 @default.
• W2028541316 hasConcept C104317684 @default.
• W2028541316 hasConcept C111599444 @default.
• W2028541316 hasConcept C126322002 @default.
• W2028541316 hasConcept C134018914 @default.
• W2028541316 hasConcept C164705383 @default.
• W2028541316 hasConcept C167414201 @default.
• W2028541316 hasConcept C170493617 @default.
• W2028541316 hasConcept C2775960820 @default.
• W2028541316 hasConcept C2776996007 @default.
• W2028541316 hasConcept C2778198053 @default.
• W2028541316 hasConcept C2778774980 @default.
• W2028541316 hasConcept C500558357 @default.
• W2028541316 hasConcept C54009773 @default.
• W2028541316 hasConcept C55493867 @default.
• W2028541316 hasConcept C71924100 @default.
• W2028541316 hasConcept C86803240 @default.
• W2028541316 hasConceptScore W2028541316C104317684 @default.
• W2028541316 hasConceptScore W2028541316C111599444 @default.
• W2028541316 hasConceptScore W2028541316C126322002 @default.
• W2028541316 hasConceptScore W2028541316C134018914 @default.
• W2028541316 hasConceptScore W2028541316C164705383 @default.
• W2028541316 hasConceptScore W2028541316C167414201 @default.
• W2028541316 hasConceptScore W2028541316C170493617 @default.
• W2028541316 hasConceptScore W2028541316C2775960820 @default.
• W2028541316 hasConceptScore W2028541316C2776996007 @default.
• W2028541316 hasConceptScore W2028541316C2778198053 @default.
• W2028541316 hasConceptScore W2028541316C2778774980 @default.
• W2028541316 hasConceptScore W2028541316C500558357 @default.
• W2028541316 hasConceptScore W2028541316C54009773 @default.
• W2028541316 hasConceptScore W2028541316C55493867 @default.
• W2028541316 hasConceptScore W2028541316C71924100 @default.
• W2028541316 hasConceptScore W2028541316C86803240 @default.
• W2028541316 hasIssue "3" @default.
• W2028541316 hasLocation W20285413161 @default.
• W2028541316 hasLocation W20285413162 @default.

• next